The numbers coming out of Mounjaro (tirzepatide) clinical trials genuinely surprised even the researchers running them. Participants lost up to 22.5% of their body weight — that’s more than any prescription weight loss medication had ever achieved in a controlled study. But what does that actually look like week by week, and how quickly can you expect to see results?
If you’re starting Mounjaro, already a few weeks in and wondering whether you’re on track, or trying to decide between Mounjaro and alternatives like Wegovy, Ozempic, or Saxenda — this breakdown is for you. We’ll walk through what the clinical data says, what real patients typically experience, and why the numbers aren’t the same for everyone.
What Is Mounjaro and How Does It Cause Weight Loss?
Mounjaro is a weekly injectable medication containing tirzepatide, a molecule that works differently from most other weight loss injections on the market. While drugs like Wegovy and Ozempic are GLP-1 receptor agonists — meaning they mimic one gut hormone to regulate appetite and blood sugar — tirzepatide targets two receptors simultaneously: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide).
This dual-action mechanism is widely believed to be the reason Mounjaro outperforms other GLP-1 receptor agonists in head-to-head comparisons. It suppresses appetite more aggressively, slows gastric emptying, and appears to improve how the body responds to insulin — all of which contribute to greater fat loss over time.
Originally approved by the FDA as a type 2 diabetes treatment, Mounjaro was later approved specifically for chronic weight management under the brand name Zepbound in the US. In the UK, it received MHRA approval for obesity treatment in 2023, and NICE subsequently recommended it for adults with a BMI of 35 or above alongside at least one weight-related condition.
The SURMOUNT Trials: Where the Data Comes From
Before looking at the week-by-week timeline, it helps to understand where these numbers originate. The weight loss data for Mounjaro comes primarily from the SURMOUNT clinical trial programme, a series of large-scale studies conducted by Eli Lilly.
The flagship study, SURMOUNT-1, followed 2,539 adults with obesity (without type 2 diabetes) over 72 weeks. Participants were randomised to receive tirzepatide at 5mg, 10mg, or 15mg doses, or a placebo — all alongside lifestyle intervention. The results were striking across every dose, but the 15mg group achieved the headline figure of 22.5% average body weight reduction.
These are averages from a controlled research setting. Real-world results vary — but they give us the most reliable framework we have for what to expect and when.
Mounjaro Weight Loss Results: Week by Week
Weeks 1–4: The Adjustment Phase
Most people starting Mounjaro begin on a 2.5mg dose, which is intentionally low. This starting dose is designed to let your body adapt to the medication — not to produce significant weight loss immediately.
During weeks one to four, you might lose between 0.5 and 2 pounds (0.2–0.9kg) per week, though some people see very little movement on the scales at all. This is normal. The primary changes happening at this stage are in your appetite and eating habits. Many people starting Mounjaro describe feeling full much faster than usual, losing interest in foods they previously craved, and eating noticeably smaller portions without feeling deprived.
A very common experience in the first month is what patients call “food noise” quieting down — that persistent background chatter about eating, snacking, and food planning that had previously occupied a lot of mental energy. For many people, this shift alone feels significant, even if the scale hasn’t moved dramatically yet.
Side effects are also most likely during this early phase. Nausea, mild digestive discomfort, and fatigue are the most reported, typically peaking in the first week after each dose increase. These usually settle within a few days.
Weeks 5–12: The Dose Escalation Window
At week five, most patients move up to 5mg — the first therapeutic dose. Some may stay at this dose for the long term; others will continue escalating toward 10mg or 15mg over the following months. This is when weight loss typically becomes more consistent and more noticeable.
Clinical data from SURMOUNT-1 shows that by week 12, participants on the 15mg dose had lost approximately 7–8% of their starting body weight on average. For someone starting at 250 lbs (113kg), that’s roughly 17–20 lbs (7.7–9kg) in three months.
Week-by-week, this phase tends to look like 1–2 lbs (0.5–1kg) per week for many patients, though some weeks will be faster and some slower. Weight loss is rarely linear — it comes in bursts, plateaus, and occasional frustrating stalls that have nothing to do with the medication failing.
Weeks 13–24 (Months 4–6): Building Momentum
By this point, most patients are on their target dose or approaching it. This is often the phase where results become most visible to others — clothes fit differently, energy levels tend to improve, and the cumulative loss becomes harder to ignore.
Average weight loss by month 6 across the SURMOUNT-1 trial was approximately 15% of body weight for the highest dose group. That equates to around 37 lbs (17kg) for someone starting at 250 lbs — though real-world patients often report both more and less than this figure depending on their diet, activity level, starting weight, and individual metabolic response.
Weeks 25–72 (Months 7–18): The Long Plateau and Final Results
Weight loss tends to slow between months six and twelve. This isn’t the medication losing effectiveness — it’s your body’s metabolic adaptation catching up. As you lose weight, your calorie requirements decrease, meaning you need to eat slightly less to keep losing at the same pace.
Patients who stay consistent through this phase continue to lose weight, just more gradually. By week 72 (roughly 17 months), the SURMOUNT-1 trial reported:
- 5mg group: Average loss of ~15% body weight
- 10mg group: Average loss of ~19.5% body weight
- 15mg group: Average loss of ~22.5% body weight
To put that in real terms, a person starting at 250 lbs on the 15mg dose would expect to lose approximately 56 lbs (25kg) by the end of the trial period — if results mirror the average.
Monthly Weight Loss Summary Table
| Month | Approximate Cumulative Weight Loss (15mg dose) |
|---|---|
| Month 1 | 2–4 lbs (1–2kg) |
| Month 3 | 15–20 lbs (7–9kg) |
| Month 6 | 30–38 lbs (14–17kg) |
| Month 9 | 40–48 lbs (18–22kg) |
| Month 12 | 48–54 lbs (22–24kg) |
| Month 17–18 | 50–60 lbs (23–27kg) |
Based on SURMOUNT-1 trial averages. Individual results vary.
How Do Mounjaro Results Compare to Wegovy, Ozempic, and Saxenda?
This is one of the most searched questions among people weighing up their options, so it deserves a straight answer.
Wegovy (semaglutide 2.4mg) is currently Mounjaro’s closest competitor. The STEP-1 trial showed average weight loss of around 14.9% of body weight over 68 weeks — meaningful results, but lower than tirzepatide’s 22.5% at the equivalent timepoint. Both are weekly injections; both require dose escalation; both produce significant appetite suppression.
Ozempic (semaglutide 1mg) is approved for type 2 diabetes management, not weight loss, though it does produce weight reduction as a side effect. The average weight loss on Ozempic is around 5–6% of body weight — substantially less than either Wegovy or Mounjaro. People sometimes ask why Ozempic and Wegovy contain the same active ingredient but produce different results — the answer is dose. Wegovy’s maximum dose of 2.4mg is significantly higher than Ozempic’s 1mg ceiling.
Saxenda (liraglutide) is a daily injection and tends to produce the most modest results of the four — around 5–8% average body weight reduction over 56 weeks, based on published clinical data. It’s often considered the entry-level option among prescription weight loss medications, and many patients who start on Saxenda later transition to a more effective treatment.
In short: for sheer weight loss magnitude, Mounjaro leads the field among currently approved options. But the “best” medication is the one that’s appropriate for your health profile, that you can access, and that you can tolerate — which is a conversation to have with your prescriber.
Why Your Mounjaro Results Might Look Different
Clinical trial averages are useful benchmarks, but they don’t capture the full picture. Several factors meaningfully influence how much weight you lose on Mounjaro and how quickly:
Starting weight. People with higher starting BMIs often see larger absolute losses in the early months, even if the percentage is similar. Someone starting at 300 lbs losing 20% loses 60 lbs; someone starting at 180 lbs losing 20% loses 36 lbs.
Diet and lifestyle. Mounjaro isn’t a passive treatment. The trial participants also received lifestyle coaching, and the medication works best when paired with consistent dietary changes. It reduces appetite significantly — but it still requires you to act on those signals.
Dose reached. Not everyone tolerates escalation to 15mg. Those who stay on lower doses will, on average, see smaller total losses. This isn’t failure — it’s individual physiology.
Metabolic health starting point. People with significant insulin resistance, hypothyroidism, or other metabolic conditions may respond differently. The NHS guidance on obesity outlines some of the underlying factors that affect weight management outcomes.
Consistency. Missing doses, especially in the early months, can disrupt the steady-state levels of medication in your system and slow progress.
When to Be Concerned About Slow Progress
Most clinical guidelines suggest that if you haven’t lost at least 5% of your body weight after 12 weeks on a therapeutic dose (not the starter 2.5mg), it’s worth discussing next steps with your prescriber. This might mean reviewing your diet, checking for any underlying conditions, or considering whether a higher dose might be appropriate.
Slow early progress is rarely a sign that the medication won’t work — it often reflects dose, dietary habits, or the normal variation in individual response. But it’s a useful checkpoint.
Conclusion
Mounjaro produces some of the most significant weight loss results of any prescription treatment currently available — and the clinical evidence behind those numbers is robust. Week by week, most people won’t see dramatic drops immediately; the medication works gradually, and the most substantial losses tend to accumulate between months three and twelve.
If you’re on Mounjaro and tracking your progress, the key is patience with the early months and consistency through the plateaus. The data is overwhelmingly in your favour over the long term.
If you’re still deciding whether Mounjaro is the right treatment for you, speak to a healthcare provider who specialises in clinical weight management. The results are genuinely impressive — but the right treatment is the one matched to your individual health picture.
Frequently Asked Questions
Q: How much weight do you lose in the first month on Mounjaro? A: Most people lose between 2 and 5 lbs (1–2.3kg) in the first month on Mounjaro, though some lose less. The first month is typically spent on the lowest starting dose of 2.5mg, which is intended to ease your body into the medication rather than maximise weight loss immediately. Appetite suppression usually begins within the first week, and eating habits often change noticeably before the scales reflect it. Don’t judge the medication’s effectiveness on month-one results alone.
Q: How long does it take for Mounjaro to start working? A: Most people notice changes in appetite and food intake within the first one to two weeks of starting Mounjaro. Measurable weight loss usually becomes more consistent from weeks four to eight onward, once the dose begins to escalate. The most significant and sustained weight loss typically occurs between months three and twelve of treatment.
Q: What is the average total weight loss on Mounjaro? A: Based on the SURMOUNT-1 clinical trial, the average total weight loss on the highest dose (15mg) was 22.5% of body weight over approximately 72 weeks. Lower doses produced average losses of around 15% (5mg) and 19.5% (10mg). Real-world results vary, but these figures represent the best-quality evidence currently available.
Q: Is Mounjaro better than Wegovy for weight loss? A: Head-to-head trial data (the SURMOUNT-5 study) and indirect comparisons consistently show Mounjaro producing greater average weight loss than Wegovy over equivalent timeframes — roughly 22.5% vs 14.9% of body weight. However, both are highly effective treatments, and the right choice depends on individual health factors, tolerability, cost, and access. Wegovy may be more suitable for some patients, and both are significantly more effective than older options like Saxenda or Ozempic.
Q: Can you get Mounjaro on the NHS for weight loss? A: As of 2024, Mounjaro is available through NHS specialist weight management services for eligible patients. NICE has recommended tirzepatide for adults with a BMI of 35 or above and at least one weight-related health condition, to be used within a specialist care pathway. Access through general practice is more limited, but private prescriptions are available through registered UK clinics. Check the NICE guidance for current eligibility criteria.
Q: What happens to your weight when you stop taking Mounjaro? A: Research shows that most people regain a significant portion of the weight they lost within one to two years of stopping Mounjaro. This is not a personal failure — it reflects the fact that obesity is a chronic condition, and the medication is managing it rather than curing it. This is why many prescribers recommend treating Mounjaro as a long-term or indefinite treatment for those who respond well to it, rather than a short course.
Q: Does Mounjaro work if you don’t change your diet? A: Mounjaro significantly reduces appetite and often changes food preferences, which naturally leads to reduced calorie intake even without deliberate dieting. However, results are meaningfully better when combined with dietary changes and increased physical activity. The clinical trials that produced the headline 22.5% figure included structured lifestyle support alongside the medication.
Additional Resources
- NICE Guidance TA1026 – Tirzepatide for Weight Management
- PubMed: SURMOUNT-1 Full Trial Results
- NHS: Obesity – Treatment Overview
- Obesity UK – Patient Information and Support
- NHS BMI Healthy Weight Calculator
- [Internal Link: Mounjaro vs Wegovy — Which Is Right for You?]
- [Internal Link: How to Qualify for Prescription Weight Loss Medication in the UK]
